COMMUNIQUÉS West-GlobeNewswire

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
10/10/2025
SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles [...]
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/10/2025
BRISBANE, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on October 6, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/10/2025
CAMBRIDGE, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/10/2025
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock [...]
Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
10/10/2025
ACTON, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced [...]
AB Science annonce aujourd’hui ses résultats financiers semestriels au 30 juin 2025 et présente un point sur ses activités
10/10/2025
COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTE SES RÉSULTATS FINANCIERS AU PREMIER SEMESTRE 2025 ET LES EVENEMENTS CLEFS DE LA PERIODE Situation financière et corporate Réduction du déficit opérationnel de 24% par rapport au [...]
AB Science today reports its revenues for the first half of 2025 and provides an update on its activities
10/10/2025
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2025 AND KEY EVENTS DURING THE PERIOD Financial and corporate situation Operating deficit reduced by 24% compared to the first half of 2024, [...]
A Wake-Up Call for Parents, Doctors & Policy Makers, "An Inconvenient Study" shines a light on one of the most important questions of our time: Why Are So Many Of Our Kids Sick?
10/10/2025
LOS ANGELES, Oct. 10, 2025 (GLOBE NEWSWIRE) -- In 2016, journalist Del Bigtree issued a challenge to the head of infectious disease at one of the most prestigious medical institutions in the world: conduct the most [...]
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
10/10/2025
FDA approves UZEDY ® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in [...]
Zacks Small-Cap Research Initiates Coverage on NewGen
10/10/2025
BANGKOK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through [...]
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million
10/10/2025
PIPE financing included participation from leading healthcare-focused institutional investors including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 [...]
Shuttle Executes LOI with Molecule.ai
10/10/2025
GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company, today [...]
Press release: Transparency Notification from Shareholder
10/10/2025
Transparency Notification from Shareholder Ghent, Belgium – 10 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of drug-resistant fluid [...]
Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025
10/10/2025
Scientific presentations reveal how Seer’s Proteograph Product Suite is a critical component of multi-omic translational studies and enables profiling of protein isoform-specific biomarkers REDWOOD CITY, Calif., Oct. 10 [...]
Inspire Medical Systems, Inc. Publishes Inspire V Data at ISSS/AAO-HNS Meetings
10/10/2025
MINNEAPOLIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive [...]
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’
10/10/2025
Presentation title: “Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine” NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “ [...]
Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
10/10/2025
– Late-breaking oral presentation highlights interim Phase 1b data reported earlier this year for two cohorts in participants with recurrent genital herpes – – Statistically significant reductions in HSV-2 shedding rate [...]
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025
10/10/2025
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced [...]
AskBio Presents Interim Safety Results from Phase 1/Phase 2 LION-CS101 Clinical Trial of AB-1003 in Participants with Limb-Girdle Muscular Dystrophy 2I/R9
10/10/2025
Research Triangle Park, N.C., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Data from first cohort of five participants suggest an acceptable safety profile for AB-1003 in participants with limb-girdle muscular dystrophy (LGMD) 2I/ [...]

Pages